ArticleBlood cancer journal2020
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities.
Article in Blood cancer journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Pulmonary amyloidosis: clinicopathologic spectrum and diagnostic pitfalls in a 12-patient case series.Journal of thoracic disease · 2026Article
- Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States.Journal of onco-nephrology · 2026Article
- Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.American journal of cardiovascular disease · 2026Article
- Cardiac Amyloidosis: Tribulations and New Frontiers.Journal of personalized medicine · 2025Review
- Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.Scientific reports · 2025Article
- Ethnicity in systemic AL amyloidosis may impact risk stratification.Haematologica · 2025Article
- Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances.Cardiology clinics · 2025Review
- Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment.Blood advances · 2024Article
- A patient with AL amyloidosis presenting with refractory tuberculosis, chest tightness and hypotension: case report.BMC pulmonary medicine · 2024Article
- A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.Cancers · 2024Article
- A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA.Journal of racial and ethnic health disparities · 2023Article
- Cardiac AL amyloidosis presenting as recurrent dyspnoea in a patient with cancer: an important clinical clue to an early diagnosis.BMJ case reports · 2022Article
- Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.Clinical hematology international · 2022Article
- Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.Blood cancer journal · 2022Observational
- Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans.Blood cancer journal · 2022Article
- Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.Methodist DeBakey cardiovascular journal · 2022Review
- Cardiac amyloidosis and surgery: What do we know about rare diseases?Journal of cardiac surgery · 2021Article
- Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.Current cardiovascular risk reports · 2021Article
- Racial disparities in patients diagnosed with light chain (AL) amyloidosis.Blood cancer journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In marked contrast to multiple myeloma, racial/ethnic minorities are underrepresented in publications of systemic light-chain (AL) amyloidosis. The impact of race/ethnicity is therefore lacking in the narrative of this disease. To address this gap, we compared disease characteristics, treatments, and outcomes across racial/ethnic groups in a referred cohort of patients with AL amyloidosis from 1990 to 2020. Among 2416 patients, 14% were minorities. Non-Hispanic Blacks (NHBs) comprised 8% and had higher-risk sociodemographic factors. Hispanics comprised 4% and presented with disproportionately more BU stage IIIb cardiac involvement (27% vs. 4-17%). At onset, minority groups were younger in age by 4-6 years. There was indication of more aggressive disease phenotype among NHBs with higher prevalence of difference between involved and uninvolved free light chains >180 mg/L (39% vs. 22-33%, P = 0.044). Receipt of stem cell transplantation was 30% lower in Hispanics compared to non-Hispanic White (NHWs) on account of sociodemographic and physiologic factors. Although the age/sex-adjusted hazard for death among NHBs was 24% higher relative to NHWs (P = 0.020), race/ethnicity itself did not impact survival after controlling for disease severity and treatment variables. These findings highlight the complexities of racial/ethnic disparities in AL amyloidosis. Directed efforts by providers and advocacy groups are needed to expand access to testing and effective treatments within underprivileged communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.